Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Summit Therapeutics plc : Director/PDMR Shareholding

Summit Therapeutics plc
Posted on: 10 Apr 18

Summit Therapeutics plc
('Summit' or the 'Company')
                                                                                                 
Exercise of Share Options

Oxford, UK, and Cambridge, MA, US, 23 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces the exercise by the following Non-Executive Directors of share options over the Company's ordinary shares of one penny nominal value granted under the Company's 2005 share option scheme. None of the new ordinary shares were sold by the Non-Executive Directors. The exercise of the options is in line with the stated intention of the Non-Executive Directors to advance the Company's objective of meeting best UK corporate governance practice that favours non-performance remuneration, such as restricted stock units.

  Number of Exercised OptionsNumber of Outstanding Options heldNew Total Shareholding% of Issued Share Capital
Barry PriceNon-Executive Director31,481Nil107,2110.13%
Stephen DaviesNon-Executive Director17,500Nil602,4810.74%

The admission of these new ordinary shares to trading on AIM is covered by the Company's existing block listing application. Following the exercise of these share options, the total number of options capable of vesting under the Company's 2005 and 2016 share option schemes is now 10,009,284.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit    
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)   +1 617 225 4455
     
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson    

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1 Details of the person discharging managerial responsibilities/person closely associated
a)NameDr Barry Price
2 Reason for the notification
a)Position / statusNon-Executive Director
b)Initial notification / AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
Identification codeGB00BN40HZ01
b)Nature of the transactionsExercise and hold of share options
c)Price(s) and volume(s)  Price(s) Volume(s)  
65 pence (exercise price)
126 pence (exercise price)
13,981
17,500
 
d)Aggregated information 
-     Aggregated volume31,481 ordinary shares
-     Price£31,137.65 (being an average subscription price of 98.9 pence per share)
e)Date of the transaction23 April 2018
f)Place of the transactionOutside a trading venue

1 Details of the person discharging managerial responsibilities/person closely associated
a)NameProfessor Stephen Davies
2 Reason for the notification
a)Position / statusNon-Executive Director
b)Initial notification / AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
Identification codeGB00BN40HZ01
b)Nature of the transactionsExercise and hold of share options
c)Price(s) and volume(s)  Price(s) Volume(s)  
126 pence (exercise price)17,500
 
d)Aggregated information 
-     Aggregated volumeN/A
-     Price 
e)Date of the transaction23 April 2018
f)Place of the transactionOutside a trading venue

-END-



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire
HUG#2186360
GlobeNewswire
globenewswire.com

Last updated on: 24/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.